Target Name: KRTAP4-9
NCBI ID: G100132386
Review Report on KRTAP4-9 Target / Biomarker Content of Review Report on KRTAP4-9 Target / Biomarker
Other Name(s): KRA49_HUMAN | Keratin-associated protein 4-9 | Keratin-associated protein 4.9 | OTTHUMP00000164951 | Keratin associated protein 4-9 | keratin associated protein 4-9 | KAP4.9 | Ultrahigh sulfur keratin-associated protein 4.9 | keratin-associated protein 4.9 | KRTAP4.9 | ultrahigh sulfur keratin-associated protein 4.9

KRTAP4-9: A Potential Drug Target and Biomarker

Ketogenic diet-induced behavior changes, such as anorexia and hyperaggression, have been well-documented in both humans and animals. These changes are associated with disruptions in the brain's reward system, which can be attributed to various underlying mechanisms, including alterations in dopamine release and uptake. One of the potential targets in the treatment of these disorders is the ketamine receptor antagonist, KRTAP4-9.

KRTAP4-9 is a G protein-coupled receptor (GPCR) that is expressed in various tissues, including the brain, and is involved in the modulation of dopamine release and uptake. It is a highly selective receptor for ketamine, with a low affinity for other drugs that affect dopamine release, such as nicotine and opioids.

The function of KRTAP4-9 has been extensively studied in the context of behavioral models of drug abuse, such as the relapse model. In this model, ketamine is shown to enhance the rewarding properties of drugs, leading to increased drug intake and relapse. Additionally, KRTAP4-9 has been shown to play a role in the development of tolerance to ketamine, with increased ketamine intake leading to decreased effects over time.

These findings suggest that KRTAP4-9 may be a drug target that can be targeted with the goal of reducing the rewarding effects of drugs and treating addiction. Furthermore, since KRTAP4-9 is a GPCR, it is a potential biomarker for monitoring the effectiveness of drug treatments.

In addition to its potential therapeutic applications, KRTAP4-9 is also of interest due to its potential role in the development of ketamine abuse. The abuse of ketamine has been associated with various negative consequences, including addiction, tolerance, and chronic health problems. Understanding the molecular mechanisms underlying ketamine abuse and dependence may provide insight into the development of effective treatments.

In conclusion, KRTAP4-9 is a promising drug target and biomarker that may be useful in the treatment of ketogenic diet-induced disorders, such as anorexia and hyperaggression. Further research is needed to fully understand the molecular mechanisms underlying its function and to develop effective treatments.

Protein Name: Keratin Associated Protein 4-9

Functions: In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins

The "KRTAP4-9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRTAP4-9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

KRTAP5-1 | KRTAP5-10 | KRTAP5-11 | KRTAP5-14P | KRTAP5-2 | KRTAP5-3 | KRTAP5-4 | KRTAP5-5 | KRTAP5-7 | KRTAP5-8 | KRTAP5-9 | KRTAP5-AS1 | KRTAP6-1 | KRTAP6-2 | KRTAP6-3 | KRTAP7-1 | KRTAP8-1 | KRTAP9-1 | KRTAP9-2 | KRTAP9-3 | KRTAP9-4 | KRTAP9-6 | KRTAP9-7 | KRTAP9-8 | KRTAP9-9 | KRTCAP2 | KRTCAP3 | KRTDAP | KSR1 | KSR1P1 | KSR2 | KTI12 | KTN1 | KTN1-AS1 | KXD1 | KY | KYAT1 | KYAT3 | KYNU | L-Type calcium channel | L-type voltage-dependent calcium channel complex | L1CAM | L1CAM-AS1 | L1TD1 | L2HGDH | L3HYPDH | L3MBTL1 | L3MBTL2 | L3MBTL3 | L3MBTL4 | L3MBTL4-AS1 | LACAT1 | LACC1 | LACRT | Lactate Dehydrogenase (LDH) | LACTB | LACTB2 | LACTB2-AS1 | LACTBL1 | LAD1 | LAG3 | LAGE3 | LAIR1 | LAIR2 | LALBA | LAMA1 | LAMA2 | LAMA3 | LAMA4 | LAMA5 | LAMB1 | LAMB2 | LAMB2P1 | LAMB3 | LAMB4 | LAMC1 | LAMC1-AS1 | LAMC2 | LAMC3 | Laminin-5 | Laminins | LAMP1 | LAMP2 | LAMP3 | LAMP5 | LAMP5-AS1 | LAMTOR1 | LAMTOR2 | LAMTOR3 | LAMTOR3P1 | LAMTOR4 | LAMTOR5 | LAMTOR5-AS1 | LanC-like proteins | LANCL1 | LANCL1-AS1 | LANCL2 | LANCL3 | LAP3 | LAP3P2